Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Grant Opportunity Analysis
The National Institute on Aging, a component of the National Institutes of Health, intends to publish a Notice of Funding Opportunity to support the Alzheimer's Drug-Development Program. Funded projects will focus on the pre-clinical and early-stage clinical Phase I development of novel small-molecule and biologic drug candidates designed to prevent, slow, or treat Alzheimer's disease. Eligible activities include preclinical drug development in applicant laboratories or in collaboration with specialized contract research organizations, aiming to expand the drug candidate pipeline and enable a precision medicine approach. This cooperative agreement opportunity will utilize the U01 activity code, and the funding announcement is anticipated to be posted on March 10, 2027, with an estimated close date of June 18, 2027.
Eligible Applicants
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
Grant Documents
No documents available for this grant.